Irina Balan

Dr. Irina Balan


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2006 in Stroke
Verified
Journal Article
Closed access
PDF file
IBIrina Balan
Irina Balan
GFGary Fiskum
Gary Fiskum
JHJulie Hazelton
Julie Hazelton
CCCynthia Cotto-Cumba
Cynthia Cotto-Cumba
RRRobert E. Rosenthal
Robert E. Rosenthal
Background and Purpose— Current guidelines suggest that cardiac arrest (CA) survivors should be ventilated with 100% O 2 after resuscitation. Breathing 100% O 2 may worsen neurological outcome after experimental CA. This study tested the hypothesis that graded reoxygenation, with oximetry guidance, can safely reduce FiO 2 after resuscitation, avoiding hypoxia while promoting neurological recovery. Methods— Mature dogs underwent 10 minutes of CA and restoration of spontaneous circulation with100% O 2. Animals were randomized to 1-hour additional ventilation on 100% FiO 2 or to rapid lowering of arterial O 2 saturation to 94% with pulse oximeter guidance. Animals were awakened at hour 23, and the neurological deficit score (0=normal; 100=brain-dead) was measured. Reanesthetized animals were perfusion-fixed and the brains removed for histopathology. Results— The neurological deficit score was significantly better in oximetry (O) dogs. O dogs appeared aware of their surroundings, whereas most hyperoxic (H) animals were stuporous (neurological deficit score=43.0±5.9 [O] versus 61.0±4.2 [H]; n=8, P <0.05). Stereological analysis revealed fewer injured CA1 neurons in O animals (cresyl violet: 35.5±4.3% [O] versus 60.5±3.3% [H]; P <0.05). There were also fewer fluoro–Jade B–stained degenerating CA1 neurons in O animals (3320±267 [O] versus 6633±356 [H] per 0.1 mm 3 ; P <0.001). Conclusions— A clinically applicable protocol designed to reduce postresuscitative hyperoxia after CA results in significant neuroprotection. Clinical trials of controlled normoxia after CA/restoration of spontaneous circulation should strongly be considered.

4 February 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
IBIrina Balan
Irina Balan
MBMatthew C. Beattie
Matthew C. Beattie
TOTodd K. O’buckley
Todd K. O’buckley
LALaure Aurelian
Laure Aurelian
AMA. Leslie Morrow
A. Leslie Morrow
The endogenous neurosteroid (3α,5α)3-hydroxypregnan-20-one (3α,5α-THP, allopregnanolone) has protective activity in animal models of alcoholism, depression, traumatic brain injury, schizophrenia, multiple sclerosis, and Alzheimer’s disease that is poorly understood. Because these conditions involve proinflammatory signaling through toll-like receptors (TLRs), we examined the effects of 3α,5α-THP, and pregnenolone on TLR4 activation in both the periphery and the central nervous system (CNS). We used monocytes/macrophages (RAW264.7) as a model of peripheral immune signaling and studied innately activated TLR4 in the ventral tegmental area (VTA) of selectively bred alcohol-preferring (P) rats. LPS activated the TLR4 pathway in RAW264.7 cells as evidenced by increased levels of p-TAK1, TRAF6, NF-κB p50, phospho-NF-κB- p65, pCREB, HMGB1, and inflammatory mediators, including MCP-1 and TNFα. Both 3α,5α-THP and pregnenolone (0.5–1.0μM) substantially (~80%) inhibited these effects, indicating pronounced inhibition of TLR4 signaling. The mechanism of inhibition appears to involve blockade of TLR4/MD-2 protein interactions in RAW246.7 cells. In VTA, 3α,5α-THP (15 mg/kg, IP) administration reduced TRAF6 (~20%), CRF (~30%), and MCP-1 (~20%) levels, as well as TLR4 binding to GABAA receptor α2 subunits (~60%) and MyD88 (~40%). The data suggest that inhibition of proinflammatory neuroimmune signaling underlies protective effects of 3α,5α-THP in immune cells and brain, apparently involving blocking of protein-protein interactions that initiate TLR4-dependent signaling. Inhibition of pro-inflammatory TLR4 activation represents a new mechanism of 3α,5α-THP action in the periphery and the brain.

8 January 2015 in Neuropsychopharmacology
Verified
Journal Article
Closed access
HJHarry L June
Harry L June
JLJuan Liu
Juan Liu
KWKaitlin T Warnock
Kaitlin T Warnock
KBKimberly A Bell
Kimberly A Bell
IBIrina Balan
Irina Balan
LALaure Aurelian
Laure Aurelian

1 April 2010 in Journal of Neurotrauma
Verified
Journal Article
Closed access
JHJulie L. Hazelton
Julie L. Hazelton
IBIrina Balan
Irina Balan
GEGreg I. Elmer
Greg I. Elmer
Tibor KristianTibor Kristian
Tibor Kristian
RRRobert E. Rosenthal
Robert E. Rosenthal
GFGary Fiskum
Gary Fiskum
In this study we tested the hypothesis that long-term neuropathological outcome is worsened by hyperoxic compared to normoxic reperfusion in a rat global cerebral ischemia model. Adult male rats were anesthetized and subjected to bilateral carotid arterial occlusion plus bleeding hypotension for 10 min. The rats were randomized to one of four protocols: ischemia/normoxia (21% oxygen for 1 h), ischemia/hyperoxia (100% oxygen for 1 h), sham/normoxia, and sham/hyperoxia. Hippocampal CA1 neuronal survival and activation of microglia and astrocytes were measured in the hippocampi of the animals at 7 and 30 days post-ischemia. Morris water maze testing of memory was performed on days 23–30. Compared to normoxic reperfusion, hyperoxic ventilation resulted in a significant decrease in normal-appearing neurons at 7 and 30 days, and increased activation of microglia and astrocytes at 7, but not at 30, days of reperfusion. Behavioral deficits were also observed following hyperoxic, but not normoxic, reperfusion. We conclude that early post-ischemic hyperoxic reperfusion is followed by greater hippocampal neuronal death and cellular inflammatory reactions compared to normoxic reperfusion. The results of these long-term outcome studies, taken together with previously published results from short-term experiments performed with large animals, support the hypothesis that neurological outcome can be improved by avoiding hyperoxic resuscitation after global cerebral ischemia such as that which accompanies cardiac arrest.

17 August 2000 in Journal of Comparative Neurology
Verified
Journal Article
Closed access
PDF file
IBIrina Balan
Irina Balan
MUMichael V. Ugrumov
Michael V. Ugrumov
ACAndré Calas
André Calas
PMPhilippe Mailly
Philippe Mailly
MKMonique Krieger
Monique Krieger
JTJean Thibault
Jean Thibault

10 January 2015 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
DBDominique Bollino
Dominique Bollino
IBIrina Balan
Irina Balan
LALaure Aurelian
Laure Aurelian
A growing body of evidence indicates that valproic acid (VPA), a histone deacetylase inhibitor used to treat epilepsy and mood disorders, has histone deacetylase‐related and ‐unrelated neurotoxic activity, the mechanism of which is still poorly understood. We report that VPA induces neuronal cell death through an atypical calpain‐dependent necroptosis pathway that initiates with downstream activation of c‐Jun N‐terminal kinase 1 (JNK1) and increased expression of receptor‐interacting protein 1 (RIP‐1) and is accompanied by cleavage and mitochondrial release/nuclear translocation of apoptosis‐inducing factor, mitochondrial release of Smac/DIABLO, and inhibition of the anti‐apoptotic protein X‐linked inhibitor of apoptosis (XIAP). Coinciding with apoptosis‐inducing factor nuclear translocation, VPA induces phosphorylation of the necroptosis‐associated histone H2A family member H2AX, which is known to contribute to lethal DNA degradation. These signals are inhibited in neuronal cells that express constitutively activated MEK/ERK and/or PI3‐K/Akt survival pathways, allowing them to resist VPA‐induced cell death. The data indicate that VPA has neurotoxic activity and identify a novel calpain‐dependent necroptosis pathway that includes JNK1 activation and RIP‐1 expression. image A growing body of evidence indicates that valproic acid (VPA) has neurotoxic activity, the mechanism of which is still poorly understood. We report, for the first time, that VPA activates a previously unrecognized calpain‐dependent necroptosis cascade that initiates with JNK1 activation and involves AIF cleavage/nuclear translocation and H2AX phosphorylation as well as an altered Smac/DIABLO to XIAP balance.